Calciphylaxis Market Share

Calciphylaxis Market Overview

The Calciphylaxis Market size is expected to reach USD 5.4 Billion by 2032 at 11.3% CAGR during the forecast period 2023-2032. Calciphylaxis or Calcific Uremic Arteriolopathy is the severe form of cardiovascular calcification in a dialysis patient. It first starts with the calcification of a small peripheral vessel and then spreads quickly all over the body. People suffering from calciphylaxis usually have calcium imbalance metabolism, which causes a deposit of calcium in the arterioles which eventually leads to the creation of blood clots in the arterioles. Blood clots cause fat tissues and lack of nourishment, and oxygen deprivation in the skin.

According to the report by NCBI, calciphylaxis affects around 4% of patients in the last stage of chronic kidney diseases, and almost 55% of people who are affected by calciphylaxis die within a year of diagnosis as they suffer from painful skin ulcers. There is a high risk of infection. There are no effective treatments found to date, and its cause is unknown. The patients suffering from this disease are treated with intensive care, including management of the wound. The occurrence of calciphylaxis is related to hyperthyroidism.

Covid-19 analysis

The sudden covid outbreak has resulted in some strict government regulation across the world, resulting in the breakage in the import and export activities of calciphylaxis treatment. Covid-19 has affected the economy globally in three main ways as by directly affecting production and demand, by creating supply chains and market breakage, and at last by financially impacting on the firms and financial markets. According to Calciphylaxis Market Analysis, the situation all around the globe explains that the market will create remunerative prospects for the producers' post covid crisis. 

Chief Factors Existing In The Market 

• Key Market Drivers

As the commonness of cardiovascular calcification in ESRD patients is increasing at a rapid pace, the Market is increasing at the same pace. The second most important factor that drives the Market is increasing healthcare expenditure; as the disease is increasing, the expenditure is also increasing. The sudden rise in research & development activities is also one of the major reasons behind the market growth. The more people get aware of the disease, the more they will opt for treatment, so awareness among patients about the treatment options is another key driver for Calciphylaxis Market growth.

• Market Challenges

Expensive Calciphylaxis Treatment

This is the major factor that is reflected as a challenge in the Market. The high cost of the treatments will hamper the Calciphylaxis Market Value. As it is expensive, most of the population will face a crisis to afford it. This results in affecting the market.

There is a high risk of infection.

The people who are affected by calciphylaxis die within a year of diagnosis as they suffer from painful skin ulcers, and there is a high risk of infection. There are no effective treatments found to date, and its cause is unknown.

• Market Opportunities

Hyperparathyroidism, along with dysregulation in calcium and phosphorous metabolism, is the major risk factor in calciphylaxis. The multi-disciplinary approach is adopted that spans nephrology, dermatopathology, dermatology, pain management and nutrition. These are the key factors that will drive the rapid evolution of the calciphylaxis treatment market. The rapidly growing number of clinical trials will have a definite positive influence on the growth of the market in the future. Whereas the randomized controlled trials for the management of calciphylaxis still lack. The collaboration of the companies is growing, with research institutes helping in the growth of the clinical trials in several places. 

The rise in the economic burden of dialysis on the health system globally is an important factor that signs well for the market. The rise in the commonness of kidney and end-stage renal diseases is a major factor that causes the demand for better calciphylaxis treatment which will bring down the repeating hospitalization and reduce morbidity. The rise in the healthcare budget for the treatment of chronic kidney disease is another major factor.

• Market Restraints

The lack in the treatment of calciphylaxis is the major factor that is affecting the Calciphylaxis Market Share and growth globally. As there is no effective treatment method available till now, it is affecting the market. The increasing research to find the suitable treatment for the disease is somehow driving the market.

Cumulative Evaluation Of The Market 

With high data integrity and industry-standard accuracy in analysis, it makes a brilliant attempt to unveil key opportunities available in the market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the Calciphylaxis market globally in terms of revenue.

Market Segmentation

The calciphylaxis market is divided on the basis of diagnosis, treatment, and end-user.

Under the diagnosis, the market is further segmented into deep skin biopsies, imaging, blood tests and others. Deep skin biopsies are further divided into shave biopsy, excisional biopsy and punch biopsy. The blood tests are further divided into serum parathormone levels, blood urea nitrogen, calcium levels, blood glucose levels and others. Imaging is further divided into magnetic resonance imaging, ultrasound, CT scan, and others.

Under the applications, the calciphylaxis market is divided into intensive wound care, clot-dissolving, medication, therapy, and others. The intensive wound care unit is again divided into debridement, wet dressings, and others. Medication is again divided into cinacalcet, sodium thiosulfate, bisphosphonates and steroids.

Under the end-user, the market is divided into hospitals, clinics, medical research centers, academic institutes, and others. 

Regional Analysis 

The calciphylaxis market is dominated by America owing to the huge development in the healthcare domain, presence of the strong economic condition, and focus of research institutions on updating new versions of technology for new and advanced treatment methods. Moreover, advanced hospitals infrastructures and the availability of skilled healthcare professionals are further adding fuel to the growth of the market. 

Europe holds the rank of second in the calciphylaxis market on the basis of changing lifestyle, increasing emphasis on rapid diagnosis and treatment of diseases, increasing commonness of diseases among the senior population. 

The Asia Pacific is the fastest growing calciphylaxis market on the basis of more number of developing nations present in this region countries such as India and China. These countries are encouraging the growth of the healthcare field. The increasing patient population of cancer in developing countries will directly raise the demand for various diagnoses & treatment methods, which will help in boosting the market growth.

The Middle East & Africa is expected to have the least market share due to less availability of medical facilities and less development in the healthcare field. However, countries such as Qatar and Kuwait are focusing more on the healthcare field and developing medical facilities, which is estimated to raise the calciphylaxis market size of this region. 

Competitive Intensity Within The Industry  

According to the offers insights into trends and prevailing intensity of competition in the factors that can significantly change the future dynamics. It evaluates the impact of the entry of new players on the competitive market. Some of the main key players with heavy investments in the calciphylaxis market are LaboratorisSanifit S.L., Medtronic Plc., ConvaTec Inc., BSN Medical, Amgen Inc., Smith & Nephew Plc. and the 3M Company. The report says that the outcome of intense study and diligent evaluation of various dynamics shapes the growth of the market.

Recent Market Developments 

• Vifor Pharma to acquire Sanifit to further strengthen the late-stage pipeline in nephrology.


• In the U.S., Helsinn Group and BridgeBio Pharma announced to update strategic collaboration to develop, manufacture and commercialize Infigratinib in Oncology indications.

Report Overview

This report includes the market overview, market strategy, calciphylaxis market trends, forecast, outlook and recent developments of the market. It shows both the opportunities and challenges of the market. The key players and how they change the market strategy.

Key Industrial Segments 

By Treatment:

• Drug Therapy


• Hyperbaric Oxygen Therapy

 By End User:

• Hospital and Clinics


• Homecare


• Ambulatory Centers

 By Region:

• North America


• Europe


• the Asia Pacific


• Latin America


• the Middle East


• Africa